Dennis Merkle

Dennis Merkle, PhD, MBA, is the Global Head of Biopharma Business and CEO of Predicine Europe. Dennis has over 20 years’ experience in Precision Oncology, having held numerous positions across both commercial and R&D functions in the pharmaceutical and diagnostics industries. Most recently he served as senior vice president of corporate development, oncology development strategy and alliance management at Invitae (formerly ArcherDx). Prior to that, Dennis was the global head of market enabling technologies and companion diagnostics at Merck KGaA, where he over-saw the development of numerous companion diagnostics across the entire Merck KGaA drug pipeline. Dennis was awarded an Alexander von Humboldt fellowship for his post-doctoral work at the Technical University of Dresden, Germany and obtained his BSc and PhD in Chemistry from the University of Calgary, Canada, focusing on DNA double-strand break repair mechanisms. Dennis also holds an MBA from Durham University Business School, UK.